Compare Iron Mountain Inc (IRM) vs Eli Lilly And Co (LLY) Price & Performance

Iron Mountain (IRM) trades at $112.97, down 3.03% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent developments highlight expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus remains bullish with a $142.75 price target, representing 26% upside potential from current levels.

IRM presents a compelling growth story in data center expansion and digital transformation, but faces significant debt burden with 79% debt-to-asset ratio. While institutional ownership is growing and earnings consistently exceed expectations, high valuation multiples and declining profit margins warrant caution. The stock's near-term performance will depend on successful execution of digital initiatives and debt management.

Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.

Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.